On 7 September 2026, UNITED LAB (03933.HK) voluntarily announced that UBT251 injection, a Class 1 innovative drug developed by its wholly-owned subsidiary United Bio-Tech, had completed first participant dosing in the Phase III clinical study for type 2 diabetes in China, which comprises UNIGUIDE-1 (360 participants, placebo-controlled) and UNIGUIDE-2 (956 participants, semaglutide-controlled). UBT251 is a long-acting GLP-1/GIP/GCG triple receptor agonist; the company is the first in China and the second globally to obtain clinical approval for such an agonist prepared by chemical synthesis of peptides, and entered into an exclusive license agreement with Novo Nordisk in March 2025.
On 7 September 2026, CSPC PHARMA (01093.HK) voluntarily announced the official initiation of the Phase II clinical trial of SYH2085 tablets for uncomplicated influenza in adults at the first center in China. SYH2085 is a Class 1 chemical small-molecule inhibitor targeting the PA subunit of the influenza virus RNA polymerase; the group obtained an NMPA Clinical Trial Approval Notice in December 2025, and Phase I data have preliminarily validated its safety and pharmacokinetic/pharmacodynamic profiles, while the multicenter, randomized, double-blind, placebo-controlled Phase II study is now recruiting and screening participants.
On 7 September 2026, MICROTECH MED-B (02235.HK) voluntarily announced that its next-generation patch-style continuous glucose monitoring system AiDEX G9 had obtained marketing approval from the NMPA, featuring an innovative change in technical architecture and comprehensive upgrades in size, lightweight design and wearing comfort over the first-generation product. Citing the IDF Diabetes Atlas 2025, the announcement noted that approximately 148 million Chinese adults aged 20-79 were living with diabetes in 2024, ranking first globally, with 274 million adults with prediabetes.
On 7 September 2026, SBP GROUP (01177.HK) voluntarily announced that TQC3721 dry powder inhaler, a PDE3/4 inhibitor developed by its subsidiary Chia Tai Tianqing, had two Phase I datasets presented at ERS 2026: a dose-ranging study in 72 COPD patients showed dose-dependent improvements in peak FEV1 at Day 9 (from 300.0 mL in the 125 μg group to 497.0 mL in the 1000 μg group), and a proof-of-concept study of the combination with glycopyrronium bromide (40 patients) showed clinically meaningful improvements versus the IND/GLY control, with FEV1 trough improving 203 mL and peak 110 mL from baseline. The nebulized suspension formulation of TQC3721 is in Phase III in China and has received CDE breakthrough therapy designation.
On 7 September 2026, HENGRUI PHARMA (01276.HK) announced that it had received NMPA Clinical Trial Approval Notices for HRS-6209 capsules and HRS-4508 tablets, approving an open-label, multicenter Phase Ib/II study of HRS-6209 in combination with other anti-tumor therapies in advanced unresectable or metastatic breast cancer and of HRS-9813 in advanced solid tumors. HRS-6209 is a novel selective CDK4 inhibitor that has advanced into Phase II, and HRS-4508 tablets are a novel selective tyrosine kinase inhibitor; cumulative R&D investment in the two projects amounts to approximately RMB 160.9 million and RMB 96.7 million respectively.
On 7 September 2026, HENGRUI PHARMA (01276.HK) announced that its subsidiary Shandong Shengdi Pharmaceutical had received an NMPA Clinical Trial Approval Notice for HRS-1597 tablets, approving clinical trials for the weight management indication. The drug is a Class 1 innovative drug independently developed by the company with no similar drug yet approved in China or overseas, and cumulative R&D investment in the project of approximately RMB 16.9 million.
On 7 September 2026, HENGRUI PHARMA (01276.HK) announced that its subsidiary Guangdong Hengrui Pharmaceutical had received an NMPA Clinical Trial Approval Notice for SHR-1179 injection, approving clinical trials for the weight management indication. The drug is a therapeutic Class 1 biological product independently developed by the company, with no drug targeting the same pathway yet approved in China or overseas, and cumulative R&D investment in the project of approximately RMB 24.2 million.
On September 7, 2026, the three major Hong Kong indices collectively retreated, with the Hang Seng Index down 0.93%, the Hang Seng TECH Index down 0.92%, and the Hang Seng China Enterprises Index down 1.46%. On that day, AI concept stocks showed divergent performance, with AI chips strengthening against the trend, while the large model and intelligent driving segments were mostly under pressure.
on September 7, 2026, the chip theme rebounded across the board, with SMIC (00981.HK) fluctuating stronger. As of 13:39, the company's quote stood at HKD 69.050, up 2.75%.
on September 7, 2026, the robotics theme strengthened, with UBTECH ROBOTICS (09880.HK) fluctuating higher. As of 13:25, the company's quote stood at HKD 87.200, up 1.81%.
On 7 September 2026, TENNOR THERAP-B (06872.HK) reported positive Phase IIa proof-of-concept data for rifaquizalone (TNP-2092) in prosthetic joint infection. Based on these data, a multicenter Phase IIb trial has been approved by the NMPA and recently initiated.
On 7 September 2026, KINTOR PHARMA-B (09939.HK) announced the completion of the long-term safety trial of KT-939, a novel tyrosinase inhibitor, on 4 September 2026, with no skin adverse reactions observed among 114 subjects after 52 weeks of continuous use of 0.2% KT-939.
On 7 September 2026, CLOVER BIO-B (02197.HK) reported positive Phase II data for respiratory combination vaccine candidates SCB-1022 (RSV + hMPV) and SCB-1033 (RSV + hMPV + PIV3) among 420 elderly subjects in Australia.
On 6 September 2026, ZHIHU-W (02390.HK) announced that Beijing Zhizhe Tansuo Technology Co., Ltd., its wholly-owned subsidiary, agreed to subscribe for limited partnership interests in Tianjin Lisi Xingshen Equity Investment Partnership (Limited Partnership) with a capital contribution of RMB 1,500,000,000; the Fund will primarily invest in early- and mid-stage unlisted AI companies in the Chinese mainland, and the subscription, constituting a major transaction, is subject to shareholders' approval at an extraordinary general meeting, with a circular expected on or before 30 September 2026.
On 6 September 2026, Baige Online Digital Technology Co., Ltd. (02672.HK) reported MaaS service revenue of approximately RMB 47.4 million for the period from 1 January to 31 August 2026, up about 579.8% year on year, with service calls exceeding 7.5 million, as its AI risk-control large-model services entered scaled commercial deployment.
On September 4, 2026, the three major Hong Kong indices opened higher and rebounded, with the Hang Seng Index up 1.74%, the Hang Seng TECH Index up 2.27%, and the Hang Seng China Enterprises Index up 2.02%.On that day, the majority of AI concept stocks rose, with the large model and intelligent driving themes mostly strengthening, while AI chips broadly weakened.
